Litcius/Paper detail

Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma

Shangxin Liu, Tianyu Wu, Dong Luo, Lele Zhang, Lu Zhou, Yiling Luo, Wenting Du, Tingting Huang, Sizun Jiang, Zhe Zhang, Ping Han, Mu‐Sheng Zeng, Qian Zhong

2025Cell Reports Medicine12 citationsDOIOpen Access PDF

Abstract

The outcome of immune checkpoint blockade (ICB) therapy largely hinges on the antitumor immunity of tertiary lymphoid structures (TLSs), but drivers of tumor TLS formation remain exclusive. By integrating spatial transcriptomics and a pan-cancer single-cell atlas, we reveal the characteristics of TLSs in nasopharyngeal carcinoma (NPC) and identify a subset of interferon-responsive high endothelial venules (IFN-HEVs) that links to the emergence of tumor-specific chemokines, especially CXCL9. Functionally, CXCL9-secreting IFN-HEVs are associated with the recruitment of CXCR3 + CD4 + T cells into TLSs. IFN-HEV-related phenotypes are strongly correlated with prolonged survival and enhanced ICB responsiveness. Leveraging these phenotypes, we develop a pretreatment CXCL9-TLS response-predictive scoring system (CTRscore), which robustly forecasts ICB therapeutic outcomes in three independent NPC cohorts. Our study provides biological and functional insights into the IFN-HEVs in tumor TLSs, highlighting their potential role in the development of biomarkers and predictors for the success of ICB therapy.

Topics & Concepts

CXCL9CXCR3ImmunotherapyNasopharyngeal carcinomaImmune checkpointCancer immunotherapyTumor-infiltrating lymphocytesChemokineCancer researchMedicineBiologyImmunologyCXCL10Immune systemChemokine receptorInternal medicineRadiation therapySingle-cell and spatial transcriptomicsCancer Immunotherapy and BiomarkersImmune cells in cancer
Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma | Litcius